Literature DB >> 7585631

A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability.

L L Myeroff1, R Parsons, S J Kim, L Hedrick, K R Cho, K Orth, M Mathis, K W Kinzler, J Lutterbaugh, K Park.   

Abstract

We have recently demonstrated that mutation of the transforming growth factor-beta (TGF-beta) receptor type II (RII) gene is characteristic of colon cancers exhibiting microsatellite instability or replication errors (RER+). Moreover, we have shown that RII mutations in these RER+ colon cancers are characteristically frameshift mutations within a 10-bp polyadenine repeat present in the RII-coding region. We now show that RII gene mutations in this polyadenine repeat are also commonly present in RER+ gastric cancers (71%). In contrast, we find these same RII gene mutations are distinctly uncommon in RER+ endometrial cancers (17%, P < 0.02). These results suggest that RII gene mutations confer a growth advantage and are selected for in RER+ cancers of both the upper and lower gastrointestinal tract. The genesis of RER+ endometrial tumors must, however, be by a different route.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585631

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

1.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

2.  Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma.

Authors:  Wei Guo; Zhiming Dong; Yanli Guo; Gang Kuang; Zhibin Yang; Baoen Shan
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.

Authors:  M A Lynch; T A Petrel; H Song; T J Knobloch; B C Casto; D Ramljak; L M Anderson; V DeGroff; G D Stoner; R W Brueggemeier; C M Weghorst
Journal:  Gene Expr       Date:  2001

4.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

5.  Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.

Authors:  Horatiu C Dancea; Mohammed M Shareef; Mansoor M Ahmed
Journal:  Mol Cell Pharmacol       Date:  2009

6.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

7.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  Targeting the transforming growth factor-beta signaling pathway in human cancer.

Authors:  Nagathihalli S Nagaraj; Pran K Datta
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

9.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

Review 10.  Aberrant crypt foci as microscopic precursors of colorectal cancer.

Authors:  Lei Cheng; Mao-De Lai
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.